SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu is capturing significant community attention as a brand-driven project focusing on organic, community-led product initiatives and IRL events. Supporters emphasize the project's consistent building efforts, widespread merchandise, and the conviction of its members as key drivers for long-term growth across multiple chains.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate Inc. is trending as investors aggressively accumulate shares in anticipation of critical upcoming catalysts, including imminent U.S. patent news and a final FDA approval decision scheduled for May 31, 2026. The community sentiment is highly optimistic, with many citing the company's proprietary Precision Timed Release technology as a potential game-changer in the massive ADHD market and debating the prospects of a strategic partnership or buyout.

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Clene Inc

Clene Inc. is trending as investors aggressively position themselves ahead of a pivotal regulatory milestone, with the community closely tracking the expected submission of an NDA for accelerated approval in ALS. Enthusiastic sentiment is fueled by anticipation of upcoming clinical biomarker data and the potential for a significant re-rating, though some investors remain cautious about the company's cash runway and the history of volatility surrounding speculative biotech catalysts.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin (XCN) is currently experiencing heightened community engagement and price volatility as traders closely monitor the upcoming Goliath mainnet launch. While some investors remain optimistic about the project's roadmap and potential for real-world asset tokenization, others are expressing skepticism and caution due to historical price trends and persistent concerns regarding transparency.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending as investors debate the impact of broader market volatility and geopolitical tensions on the stock's recent price compression, with the community sharply divided between those calling for a bottom-fishing opportunity based on strong margins and those fearing further downside. Discussion is heavily focused on potential squeeze setups, option positioning, and the stock's tendency to detach from broader software market recoveries.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as traders attempt to hedge against geopolitical instability in the Middle East, with community discussion intensely focused on whether current volatility levels accurately reflect potential supply chain disruptions and oil price shocks. Investors remain divided, debating whether this is a genuine hedge for a broader market correction or a 'widowmaker' trap subject to structural decay that favors short-term scalping over long-term holding.

Tidal Trust II - YieldMax MSTR Option Income Strategy ETF

YieldMax MSTR Option Income Strategy ETF

MSTY is trending as investors react to a planned reverse stock split and ongoing volatility in its underlying asset, MicroStrategy. The community remains deeply divided, with some traders leveraging the fund's income-generating strategy through inverted pair hedging, while others express frustration over persistent share price erosion and reduced dividend payouts.

Fluence Energy, Inc. engages in energy storage products and services, and artificial intelligence-enabled digital applications for renewables and storage. Its storage includes Smartstack, Gridstack Pro, Grisdtack, and Ultrastack. The company was founded on June 21, 2021, and is headquartered in Arlington, VA.

Fluence Energy Inc - Ordinary Shares - Class A

Fluence Energy is drawing significant investor interest as the company shifts from recent margin-related volatility to a narrative of robust backlog growth and expanding data center demand, buoyed by positive analyst upgrades and a record-high order intake. The community is actively debating the company's potential as a critical infrastructure play for AI-driven power needs, with many focusing on whether recent operational improvements will finally bridge the gap between their massive project pipeline and sustained profitability.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The crow with knife community is actively celebrating the project's two-year anniversary while highlighting its multi-chain presence and deflationary tokenomics. Investors remain vocal about upcoming developments and the strength of their organic, community-driven approach.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently trending as investors monitor ongoing discussions with the FDA regarding the clinical hold on its Phase 3 MAGNITUDE trials. The community is actively debating the stock's high short interest and the potential for a rapid recovery, with many focused on the upcoming clinical data readouts as a key catalyst.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alpha Cognition Inc. (NASDAQ:ACOG) Sees Significant Growth in Short Interest

Alpha Cognition Inc. (NASDAQ:ACOG - Get Free Report) was the target of a large growth in short interest in February. As of February 27th, there was short interest totaling 317,725 shares, a growth of...

Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026

Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its fourth quarter and full year...

Alpha Cognition to Present New Clinical on ZUNVEYL (Benzgalantamine) at Multiple Upcoming Alzheimers Association International Conferences

Alpha Cognition Inc. (Nasdaq: ACOG) (Alpha Cognition or the Company), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it...

Alpha Cognition Inc. (NASDAQ:ACOG) Short Interest Down 32.1% in February

Alpha Cognition Inc. (NASDAQ:ACOG - Get Free Report) saw a significant decline in short interest in February. As of February 13th, there was short interest totaling 228,500 shares, a decline of 32.1...

Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study

Alpha Cognition Inc. (NASDAQ: ACOG) (Alpha Cognition, ACI, or the Company), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases...

Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL Dosing Regimens

Alpha Cognition Inc. (NASDAQ: ACOG) (Alpha Cognition, ACI, or the Company), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today...

Alpha Cognition (NASDAQ:ACOG) Trading Up 13.3% - Here's What Happened

Alpha Cognition (NASDAQ:ACOG) Stock Price Up 13.3% - Should You Buy...

Alpha Cognition Inc. (NASDAQ:ACOG) Short Interest Update

Alpha Cognition Inc. (NASDAQ:ACOG - Get Free Report) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 250,001 shares, a growth of...

Alpha Cognition Inc. (NASDAQ:ACOG) Short Interest Up 60.0% in December

Alpha Cognition Inc. (NASDAQ:ACOG - Get Free Report) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totaling 167,235 shares, a...

Alpha Cognition (NASDAQ:ACOG) Given "Buy" Rating at HC Wainwright

HC Wainwright restated a "buy" rating and set a $18.00 price objective on shares of Alpha Cognition in a research report on Friday...

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. It has additional pre-clinical development programs: ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease, ALPHA-1062 sublingual formulation, ALPHA-1062 intranasal (“ALPHA-1062IN”) formulation for the treatment of cognitive impairment with mild traumatic brain injury (mTBI, otherwise known as concussion) and ALPHA-0602, ALPHA-0702 & ALPHA-0802. The company was founded in 2000 and is headquartered in Grapevine, TX.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.27	--	--	N/A
Q3 '25	-$0.43	-$0.08	81.40%	BEAT
Q2 '25	-$0.46	-$0.65	-41.30%	MISSED
Q1 '25	-$0.58	-$0.58	--	EXPECTED
Q4 '24	-$0.63	-$0.51	19.05%	BEAT

ACOG
Alpha Cognition Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest ACOG News

ACOGAlpha Cognition Inc